Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.17 Consensus PT from Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has received a consensus rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $62.1667.

SUPN has been the subject of a number of research analyst reports. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, March 8th. Finally, Stifel Nicolaus increased their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 4,475 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total transaction of $228,269.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Georges Gemayel sold 10,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $53.71, for a total transaction of $537,100.00. Following the transaction, the director owned 28,159 shares in the company, valued at approximately $1,512,419.89. This trade represents a 26.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 120,881 shares of company stock valued at $6,139,356 over the last three months. Insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in SUPN. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Supernus Pharmaceuticals by 8.8% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock valued at $453,000 after purchasing an additional 1,161 shares in the last quarter. Ruffer LLP bought a new stake in Supernus Pharmaceuticals in the 3rd quarter worth about $2,647,000. XTX Topco Ltd bought a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $1,301,000. Systematic Financial Management LP increased its stake in Supernus Pharmaceuticals by 47.5% in the 2nd quarter. Systematic Financial Management LP now owns 245,545 shares of the specialty pharmaceutical company’s stock valued at $7,740,000 after buying an additional 79,041 shares during the last quarter. Finally, Jefferies Financial Group Inc. increased its stake in Supernus Pharmaceuticals by 62.0% in the 3rd quarter. Jefferies Financial Group Inc. now owns 86,179 shares of the specialty pharmaceutical company’s stock valued at $4,118,000 after buying an additional 32,979 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $49.52 on Friday. The company has a market cap of $2.85 billion, a price-to-earnings ratio of -72.82, a PEG ratio of 1.54 and a beta of 0.70. Supernus Pharmaceuticals has a 12 month low of $29.16 and a 12 month high of $59.68. The stock has a 50-day moving average price of $50.99 and a two-hundred day moving average price of $49.39.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.